Skip to content

US · MNOV · BIOTECHNOLOGY

MediciNova, Inc. (MNOV) intrinsic value and stock valuation

$1.31as of 2026-11-21 · Mkt cap 65.46M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MediciNova, Inc. DCF and intrinsic value

InvestorsCraft values MNOV with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MNOV’s statements →

MediciNova, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology La Jolla, CA 92037 medicinova.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$410K
20112025
Net income
-$-12M
20112025
Free cash flow
-$-9.81M
20112025
Total equity
$41.6M-10.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$410K$0.00$1M$0.00$4.04M
Operating income-$-13.28M-$-12.68M-$-9.9M-$-14.63M-$-10.22M
Net income-$-12M-$-11.05M-$-8.57M-$-14.07M-$-10.13M
EPSd-$-244.6K-$-225.28K-$-174.72K-$-286.85K-$-208.44K
Operating cash flow-$-9.81M-$-10.64M-$-7.43M-$-12.91M-$-9.38M
Capital expenditure-$0.00-$0.00-$-20K-$-10K-$-30K
Free cash flow-$-9.81M-$-10.64M-$-7.45M-$-12.92M-$-9.41M
Total assets$45.6M$55.9M$66.3M$74.2M$87.4M
Total debt$190K$190K$220K$680K$830K
Net debt-$-30.61M-$-40.17M-$-50.78M-$-17.82M-$-70.6M
Total equity$41.6M$52.5M$62.4M$70.2M$83.7M
Cash and short-term investments$30.8M$40.4M$51M$58.5M$71.4M
Income statement
20252024202320222021
Revenue$410K$0.00$1M$0.00$4.04M
Cost of revenue$380K$0.00$0.00$0.00$0.00
Gross profit$30K$0.00$1M$0.00$4.04M
Research and development expenses$7.16M$7.2M$5.66M$9.14M$8.1M
Selling, general and administrative expenses$6.16M$5.48M$5.24M$5.48M$5.72M
Other expenses-$0.00-$0.00-$0.00$0.00$440K
Operating expenses$13.3M$12.7M$10.9M$14.6M$14.3M
Cost and expenses$13.7M$12.7M$10.9M$14.6M$14.3M
Interest income$1.3M$1.67M$1.83M$810K$140K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$20K$20K$20K$20K$30K
Ebitda-$-11.97M-$-11.02M-$-8.55M-$-14.05M-$-10.11M
Operating income-$-13.28M-$-12.68M-$-9.9M-$-14.63M-$-10.22M
Total other income/expenses, net$1.29M$1.63M$1.33M$560K$80K
Income before tax-$-11.99M-$-11.04M-$-8.57M-$-14.07M-$-10.13M
Income tax expense$10K$10K$0.00$0.00$0.00
Net income-$-12M-$-11.05M-$-8.57M-$-14.07M-$-10.13M
Weighted average shares outstanding$49.1M$49.1M$49.1M$49.1M$48.6M
Weighted average diluted shares outstanding$49.1M$49.1M$49.1M$49.1M$48.6M
Balance sheet
20252024202320222021
Cash and short-term investments$30.8M$40.4M$51M$58.5M$71.4M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$31M$41.1M$51.2M$59M$72M
Property, plant and equipment, net$190K$380K$620K$670K$880K
Goodwill and intangible assets$14.4M$14.4M$14.4M$14.4M$14.4M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$14.6M$14.8M$15.1M$15.2M$15.4M
Total assets$45.6M$55.9M$66.3M$74.2M$87.4M
Accounts payable$620K$1.1M$1M$420K$400K
Short-term debt$190K$190K$220K$160K$130K
Deferred revenue$370K$0.00$0.00$0.00$0.00
Total current liabilities$3.8M$2.96M$3.28M$3.19M$2.83M
Long-term debt$0.00$0.00$0.00$520K$690K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$220K$410K$610K$730K$900K
Capital lease obligations$190K$190K$220K$680K$830K
Total liabilities$4.02M$3.37M$3.89M$3.91M$3.73M
Common stock$50K$50K$50K$50K$50K
Retained earnings-$-438.75M-$-426.75M-$-415.7M-$-407.13M-$-393.06M
Accumulated other comprehensive income (loss)-$-130K-$-140K-$-120K-$-120K-$-100K
Total equity$41.6M$52.5M$62.4M$70.2M$83.7M
Total investments$0.00$0.00$0.00$40M$0.00
Total debt$190K$190K$220K$680K$830K
Net debt-$-30.61M-$-40.17M-$-50.78M-$-17.82M-$-70.6M
Cash flow statement
20252024202320222021
Net income-$-12M-$-11.05M-$-8.57M-$-14.07M-$-10.13M
Depreciation and amortization$20K$20K$20K$20K$30K
Stock-based compensation$830K$1.19M$710K$640K$1.72M
Change in working capital$1.17M-$-980K$110K$330K-$-1.21M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$460K-$-310K$20K$330K-$-1.03M
Net cash provided by operating activities-$-9.81M-$-10.64M-$-7.43M-$-12.91M-$-9.38M
Investments in property, plant and equipment-$0.00-$0.00-$-20K-$-10K-$-30K
Acquisitions, net$0.00$0.00$0.00$5.01M$0.00
Net cash used for investing activities-$0.00-$0.00$39.9M-$-40.01M-$-30K
Common stock issued$0.00$0.00$0.00$10K$20.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$240K$0.00$0.00$10K$20.8M
Net change in cash-$-9.55M-$-10.64M$32.5M-$-52.93M$11.4M
Cash at end of period$30.8M$40.4M$51M$18.5M$71.4M
Operating cash flow-$-9.81M-$-10.64M-$-7.43M-$-12.91M-$-9.38M
Capital expenditure-$0.00-$0.00-$-20K-$-10K-$-30K
Free cash flow-$-9.81M-$-10.64M-$-7.45M-$-12.92M-$-9.41M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MediciNova, Inc.

        MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.

        CEO
        Yuichi Iwaki
        Employees
        6
        Beta
        0.62

        Explore

        Frequently asked questions

        What is the intrinsic value of MediciNova, Inc. (MNOV)?

        InvestorsCraft does not currently publish an intrinsic value for MNOV. How the IC value is calculated.

        Is MNOV undervalued?

        InvestorsCraft does not publish an undervaluation signal for MNOV at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.